Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma

Cancer

Volumn 116, Issue 6, 2010, Pages 1495-1501

  Spina, Michele ^a   Chimienti, Emanuela ^a   Martellotta, Ferdinando ^a   Vaccher, Emanuela ^a   Berretta, Massimiliano ^a   Zanet, Ernesto ^a   Lleshi, Arben ^a   Canzonieri, Vincenzo ^a   Bulian, Pietro ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Human immunodeficiency virus infection; Liposomal cytarabine; Non Hodgkin lymphoma; Prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EFAVIRENZ; ETOPOSIDE; FLUCONAZOLE; FOSAMPRENAVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOPINAVIR PLUS RITONAVIR; METHOTREXATE; NEVIRAPINE; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LARGE CELL LYMPHOMA; LYMPHOMATOUS MENINGITIS; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMABLASTIC LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; RISK REDUCTION; SOMNOLENCE; VIRUS CARCINOGENESIS;

ADOLESCENT; ADULT; CYTARABINE; DRUG EVALUATION; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, SPINAL; LIPOSOMES; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED;

EID: 77949358076     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24922     Document Type: Article

References (53)

1. Herman TS, Hammond N, Jones SE, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma. Cancer. 1979;43:390-397.
2. Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17:2479-2485.
3. Bos GM, van Putten WL, van der HB, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998;9:191-194.
4. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099-1107.
5. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178-1184.
6. Sandlund JT, Murphy SB, Santana VM, et al. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:3018-3024.
7. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15:129-133.
8. Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am. 2005;19:751-763.
9. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35:487-496.
10. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkin's lymphoma-a multivariate analysis. Acta Oncol. 1996;35:703-708.
11. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 1996; 14:941-944.
12. Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27:61-70.
13. Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 1999;32: 571-576.
14. Litam JP, Cabanillas F, Smith TL, et al. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood. 1979;54:1249-1257.
15. Bashir RM, Bierman PJ, Vose JM, et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 1991;14:478-482.
16. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin's lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1556-1564.
17. Vaccher E, Tirelli U, Spina M, et al. Age and serum lactate dehydrogenase level are independent prognostic factors in HIV-related non-Hodgkin's lymphoma: a single institution study of 96 patients. J Clin Oncol. 1996;14:2217-2233.
18. Tirelli U, Spina M, Vaccher E, et al. Clinical evaluation of 451 patients with HIV related non-Hodgkin's lymphoma: experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). Leuk Lymphoma. 1995;20:91-96.
19. Sparano JA. Clinical aspects and management of AIDSrelated lymphoma. Eur J Cancer. 2001;37:1296-1305.
20. Desai J, Mitnick R, Henry D, et al. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin's lymphoma. Cancer. 1999;86:1840-1847.
21. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641-1648.
22. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:3325-3330.
23. Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS. 2003;17:861-865.
24. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394-3402.
25. Glantz MJ, LaFollette S, Kurt A, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116.
26. Sancho JM, Ribera JM, Romero MJ, et al. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica. 2006;91:ECR02.
27. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22:3916-3921.
28. Parasole R, Menna G, Marra N, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of 2 pediatric institutions. Leuk Lymphoma. 2008;49:1553-1559.
29. Rueda Dominguez A, Olmos Hidalgo D, Viciana Garrido R, et al. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol. 2005;7:232-238.
30. Jaeckle KA, Phuphanic S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84:157-163.
31. Mazhar D, Stebbing J, Lewis R, et al. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood. 2006;107:3412-3414.
32. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13: 193-207.
33. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on non-Hodgkin's disease classification. Cancer Res. 1971;31:1860-1861.
34. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:4123-4128.
35. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (RCDE) in HIV-associated non-Hodgkin's lymphoma: pooled results from 3 phase II trials. Blood. 2005;105:1891-1897.
36. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006; 107:3832-3840.
37. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13: 1264-1274.
38. Bernstein JI, Coleman CN, Strickler JG, et al. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986;4:847-858.
39. McClune B, Buadi FK, Aslam N, et al. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma. 2007;48:1849-1851.
40. Cheson BD, Horning S, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
41. Miller AB, Hoogstragen B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
42. Simon R. Designs for efficient clinical trials. Oncology. 1989;3:47-49.
43. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
44. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
45. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive lymphoma. N Engl J Med. 1993;329:987-994.
46. Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214-3218.
47. Sommer C, Lackner H, Benesch M, et al. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in 3 adolescents with acute myeloid leukaemia. Ann Hematol. 2008;87:887-890.
48. Zimm S, Collins JM, Miser J, et al. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984;35: 826-830.
49. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186-2193.
50. Kim S, Khatibi S, Howell SB, et al. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into Depo-Foam. Cancer Res. 1993;53:1596-1598.
51. Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896-3902.
52. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101: 4653-4659.
53. Kristensen MS, Sloth E, Jensen TK. Relationship between anesthetic procedure and contact of anesthesia personnel with patient body fluids. Anesthesiology. 1990;73:619-624.